Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits

Rachel E. Sachs is the Treiman Professor of Law at Washington University in St. Louis. She teaches and writes about innovation policy, exploring the interaction of intellectual property law, food and drug regulation, and health law. Before joining Washington University in St. Louis, she was an academic fellow with the Petrie-Flom Center at Harvard Law School. rsachs@wustl.edu

Shelley A. Jazowski is a postdoctoral research fellow at Vanderbilt University Medical Center. Her research focuses on the cost and utilization of prescription medications as well as the identification and assessment of interventions for improving access to and equity of care.

Kyle A. Gavulic is an MD/PhD candidate at the Yale School of Medicine, where he is pursuing a PhD in health policy. His current research focuses on prescription drug policy, Medicaid policy, and access to care for underserved populations.

Julie M. Donohue is professor and chair of the Department of Health Policy and Management at the University of Pittsburgh, where she also directs the Medicaid Research Center. She conducts research on insurance coverage, financing, and health care delivery, focusing primarily on the use of prescription drugs and mental health care. She has studied the impact of several expansions of public insurance on health care access, quality, and costs. She also examines organizational, industry, and policy influences on physician prescribing.

Stacie B. Dusetzina is an associate professor with the Department of Health Policy and an Ingram Associate Professor of Cancer Research at the Vanderbilt University School of Medicine. She is a health services researcher focusing on the intersection between health policy, epidemiology, and economics related to prescription drugs. Her work has contributed to the evidence base for the role of drug costs in patient access to care and to policy changes that might improve patient access to high-priced drugs.